Enliven Therapeutics, Inc. (ELVN) has 9 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 4 sales totalling $40.2M. Most recent filing: Aug. 19, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Aug. 19, 2026 filed Aug. 17, 2026 | Hohl Benjamin CHIEF FINANCIAL OFFICER | −$352,551 | 6,018 | −13% | Yes | |
|
|
||||||
| Aug. 19, 2026 filed Aug. 17, 2026 | Collins Helen Louise CHIEF MEDICAL OFFICER | $280,531 | 15,000 | 0% | Yes | |
|
|
||||||
| Aug. 6, 2026 filed Aug. 4, 2026 | Derynck Mika K Director | $9,167,775 | 476,385 | — | Yes | |
|
|
||||||
| July 21, 2026 filed July 17, 2026 | Hohl Benjamin CHIEF FINANCIAL OFFICER | −$260,352 | 8,162 | −6% | Yes | |
|
|
||||||
| July 21, 2026 filed July 17, 2026 | Collins Helen Louise CHIEF MEDICAL OFFICER | $250,973 | 15,000 | 0% | Yes | |
|
|
||||||
Showing the 5 most recent of 9 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free